{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:08:50Z","timestamp":1784326130568,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000089","name":"Medical Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2025.100184","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:45:01Z","timestamp":1763621101000},"page":"100184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-1982","authenticated-orcid":false,"given":"Adam","family":"Suleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zharmaine","family":"Ante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-475X","authenticated-orcid":false,"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bneo.2025.100184_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2025.100184_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2025.100184_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100184_bib4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100184_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.bneo.2025.100184_bib6","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100184_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.bneo.2025.100184_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.bneo.2025.100184_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9873","key":"10.1016\/j.bneo.2025.100184_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.bneo.2025.100184_bib11","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2025.100184_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2025.100184_bib13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2025.100184_bib14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100184_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100184_bib16","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100184_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100184_bib18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-018-0265-7","article-title":"Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables","volume":"54","author":"Tay","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bneo.2025.100184_bib19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bmt.2010.94","article-title":"How we approach patient evaluation for hematopoietic stem cell transplantation","volume":"45","author":"Hamadani","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bneo.2025.100184_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2020.10.009","article-title":"Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100184_bib21","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1002\/ajh.26957","article-title":"Socioeconomic marginalization and health outcomes in newly diagnosed multiple myeloma: a population-based cohort study","volume":"98","author":"Visram","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100184_bib22","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MLR.0b013e318229360e","article-title":"The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins Aggregated Diagnosis Groups to predict mortality in a general adult population cohort in Ontario, Canada","volume":"49","author":"Austin","year":"2011","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.bneo.2025.100184_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/hematolrep16010006","article-title":"Survival outcomes of patients with mantle cell lymphoma: a retrospective, 15-year, real-life study","volume":"16","author":"Cencini","year":"2024","journal-title":"Hematol Rep"},{"issue":"1","key":"10.1016\/j.bneo.2025.100184_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jha2.311","article-title":"Mantle cell lymphoma treatment options for elderly\/unfit patients: a systematic review","volume":"3","author":"Alnassfan","year":"2022","journal-title":"eJHaem"},{"issue":"1","key":"10.1016\/j.bneo.2025.100184_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bjh.18597","article-title":"Survival of patients with mantle cell lymphoma in the rituximab era: retrospective binational analysis between 2000 and 2020","volume":"201","author":"Harmanen","year":"2023","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100184_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100184_bib28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100184_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100184_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10441","key":"10.1016\/j.bneo.2025.100184_bib31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"The Lancet"},{"issue":"suppl 15","key":"10.1016\/j.bneo.2025.100184_bib32","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100184_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/bjh.18972","article-title":"Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario","volume":"202","author":"Suleman","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2025.100184_bib34","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:26Z","timestamp":1779294446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328025001190"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100184","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100184"}}